<DOC>
	<DOCNO>NCT00369278</DOCNO>
	<brief_summary>This study ass association initially intensify dose regimen enteric-coated mycophenolate sodium ( EC-MPS ) first 6 week post renal transplantation acute rejection relative rapid achievement MPA ( mycophenolic acid ) exposure â‰¥ 40 mg*h/L compare standard dose regimen EC-MPS . Additionally , study assess safety tolerability intensify dose regimen EC-MPS . This study conduct 2 stage ( Stage I Stage II ) .</brief_summary>
	<brief_title>Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion Corticosteroid Combination Patients With de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criterion 1 . Recipients de novo cadaveric , live unrelated living relate kidney transplant 2 . Females capable become pregnant must negative serum pregnancy test within 7 day prior baseline , required practice approve method birth control duration study period 6 week follow discontinuation study medication , even history infertility . 3 . Patients willing able participate study write informed consent obtain . Exclusion criteria 1 . More one previous renal transplantation 2 . Graft loss due immunological reason first year transplantation ( case secondary transplantation ) 3 . Multiorgan recipient ( e.g. , kidney pancreas ) previous transplant organ , different kidney 4 . Patients receive kidney nonheart beat donor 5 . Patients recipient ABO incompatible transplant Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Renal transplantation , mycophenolate</keyword>
</DOC>